Acupoint catgut embedding advantage in treating gastro-oesophageal reflux disease (ACE-GERD): study protocol for a randomised controlled trial

被引:0
|
作者
Wen, Shuting [1 ]
Zhao, Xiying [1 ]
Lin, Xiaofeng [1 ]
Fu, Zhaoli [1 ]
Qin, Shumin [1 ]
Pan, Qimou [1 ]
Liu, Fengbin [2 ]
He, Wenfang [1 ]
Liu, Tianwen [1 ]
机构
[1] Guangzhou Univ Chinese Med, Dept Gastroenterol, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China
[2] Guangzhou Univ Tradit Chinese Med, Dept Gastroenterol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
来源
BMJ OPEN | 2024年 / 17卷 / 10期
关键词
Gastroenterology; Anxiety disorders; Depression & mood disorders; PUMP INHIBITORS; ACUPUNCTURE; DEPRESSION; MECHANISMS; THERAPY; ANXIETY;
D O I
10.1136/bmjopen-2023-081059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Gastro-oesophageal reflux disease (GERD) is a highly prevalent disorder worldwide and developing effective treatment strategies for GERD is a clinical priority. GERD is associated with anxiety and depression. Several approaches have been developed to improve GERD, although effectiveness is limited. Acupoint catgut embedding (ACE) is an established technique in traditional Chinese medicine for the treatment of anxiety and depression. This study will investigate the effects of ACE on anxiety, depression, acid reflux and heartburn in patients with GERD. Methods The ACE-GERD trial is a single-centre, prospective randomised controlled trial. 62 patients will be randomly assigned equally to the experimental and control groups. Patients will be treated with ACE or sham ACE. In the experimental group, absorbable polyglycolic acid sutures will be implanted at the acupoints using sterile disposable injection needles. The sham ACE treatment will exhibit similar surface characteristics but lack absorbable polyglycolic acid sutures. Treatments will be administered every 2 weeks for a period of 10 weeks. The main outcome measure is the Reflux Disease Questionnaire symptom score. Secondary outcomes are the endoscopic assessment, 24-hour pH/impedance monitoring test, oesophageal high-resolution manometer, Gastro-oesophageal Reflux Disease Questionnaire score, Gastro-oesophageal Reflux Disease Health-related Quality of Life, Self-rating Anxiety Scale and Self-rating Depression Scale scores. Discussion The ACE-GERD trial aims to evaluate the efficacy of ACE treatment as a therapeutic tool for improving anxiety, depression, acid reflux and heartburn in patients with GERD and to provide the evidence base for future clinical studies. Ethics and Dissemination The trial has been approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (ethics no. BF2023-113-01). Results will be published in peer-reviewed journals and presented at scientific conferences and meetings.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Carditis in patients with gastro-oesophageal reflux disease: results of a controlled study based on both endoscopy and 24-h oesophageal pH monitoring
    Zentilin, P
    Mastracci, L
    Dulbecco, P
    Gambaro, C
    Bilardi, C
    Ceppa, P
    Spaggiari, P
    Iiritano, E
    Mansi, C
    Vigneri, S
    Fiocca, R
    Savarino, V
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (12) : 1285 - 1292
  • [42] Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole
    Liu, Wenjun
    Xie, Yong
    Li, Yingmeng
    Zheng, Longjin
    Xiao, Qiuping
    Zhou, Xu
    Li, Qiong
    Yang, Ni
    Zuo, Kexuan
    Xu, Tielong
    Lu, Nong-Hua
    Zhang, Heping
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [43] Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole
    Wenjun Liu
    Yong Xie
    Yingmeng Li
    Longjin Zheng
    Qiuping Xiao
    Xu Zhou
    Qiong Li
    Ni Yang
    Kexuan Zuo
    Tielong Xu
    Nong-Hua Lu
    Heping Zhang
    BMC Gastroenterology, 22
  • [44] Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial)
    Grant, A. M.
    Boachie, C.
    Cotton, S. C.
    Faria, R.
    Bojke, L.
    Epstein, D. M.
    Ramsay, C. R.
    Corbacho, B.
    Sculpher, M.
    Krukowski, Z. H.
    Heading, R. C.
    Campbell, M. K.
    HEALTH TECHNOLOGY ASSESSMENT, 2013, 17 (22) : 1 - +
  • [45] Does eradication of Helicobacter pylori influence the recurrence of symptoms in patients with symptomatic gastro-oesophageal reflux disease?: A randomised double blind study
    Axon, ATR
    Bardhan, K
    Moayyedi, P
    Dixon, MF
    Brown, L
    GASTROENTEROLOGY, 1999, 116 (04) : A117 - A117
  • [46] Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs. usual primary care for GERD: pooled analysis of five cluster-randomised European studies
    Ponce, J.
    Garrigues, V.
    Agreus, L.
    Tabaglio, E.
    Gschwantler, M.
    Guallar, E.
    Tafalla, M.
    Nuevo, J.
    Hatlebakk, J.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (09) : 897 - 905
  • [47] The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial
    Grant, A.
    Wileman, S.
    Ramsay, C.
    Boike, L.
    Epstein, D.
    Sculpher, M.
    Macran, S.
    Kilonzo, M.
    Vale, L.
    Francis, J.
    Mowat, A.
    Krukowski, Z.
    Heading, R.
    Thursz, M.
    Russell, I.
    Campbell, M.
    HEALTH TECHNOLOGY ASSESSMENT, 2008, 12 (31) : 1 - +
  • [48] Does eradication of Helicobacter pylori influence the recurrence of symptoms in patients with symptomatic gastro-oesophageal reflux disease?: A randomised double blind study.
    Moayyedi, P
    Bardhan, KD
    Wrangstadh, M
    Dixon, MF
    Brown, L
    Axon, ATR
    GUT, 1999, 44 : A112 - A112
  • [49] Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole
    Morgan, D.
    Pandolfino, J.
    Katz, P. O.
    Goldstein, J. L.
    Barker, P. N.
    Illueca, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (02) : 200 - 208
  • [50] Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms
    Moraes-Filho, J. P.
    Pedroso, M.
    Quigley, E. M. M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (01) : 47 - 56